Than NN, Newsome PN. A concise review of non-alcoholic fatty liver disease. Atherosclerosis 2015; 239: 192–202.
Brown GT, Kleiner DE. Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Metabolism 2015; 65: 1080–1086.
Yki-Jarvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol 2014; 2: 901–910.
Yki-Jarvinen H. Nutritional modulation of non-alcoholic fatty liver disease and insulin resistance. Nutrients 2015; 7: 9127–9138.
Auguet T, Berlanga A, Guiu-Jurado E, Martinez S, Porras JA, Aragones G et al. Altered fatty acid metabolism-related gene expression in liver from morbidly obese women with non-alcoholic fatty liver disease. Int J Mol Sci 2014; 15: 22173–22187.
Baffy G. MicroRNAs in nonalcoholic fatty liver disease. J Clin Med 2015; 4: 1977–1988.
Ambros V. The functions of animal microRNAs. Nature 2004; 431: 350–355.
Ying SY, Chang DC, Miller JD, Lin SL. The microRNA: overview of the RNA gene that modulates gene functions. Methods Mol Biol 2006; 342: 1–18.
Louten J, Beach M, Palermino K, Weeks M, Holenstein G. MicroRNAs expressed during viral infection: biomarker potential and therapeutic considerations. Biomark Insights 2016; 10: 25–52.
Bronte F, Bronte G, Fanale D, Caruso S, Bronte E, Bavetta MG et al. HepatomiRNoma: the proposal of a new network of targets for diagnosis, prognosis and therapy in hepatocellular carcinoma. Crit Rev Oncol Hematol 2016; 97: 312–321.
Bettermann K, Hohensee T, Haybaeck J. Steatosis and steatohepatitis: complex disorders. Int J Mol Sci 2014; 15: 9924–9944.
Cheung O, Puri P, Eicken C, Contos MJ, Mirshahi F, Maher JW et al. Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology 2008; 48: 1810–1820.
Leti F, Malenica I, Doshi M, Courtright A, Van Keuren-Jensen K, Legendre C et al. High-throughput sequencing reveals altered expression of hepatic microRNAs in nonalcoholic fatty liver disease-related fibrosis. Transl Res 2015; 166: 304–314.
Soronen J, Yki-Jarvinen H, Zhou Y, Sadevirta S, Sarin AP, Leivonen M et al. Novel hepatic microRNAs upregulated in human nonalcoholic fatty liver disease. Physiol Rep 2016; 4: 1.
Li S, Chen X, Zhang H, Liang X, Xiang Y, Yu C et al. Differential expression of microRNAs in mouse liver under aberrant energy metabolic status. J Lipid Res 2009; 50: 1756–1765.
Pirola CJ, Fernandez Gianotti T, Castano GO, Mallardi P, San Martino J, Mora Gonzalez Lopez Ledesma M et al. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut 2015; 64: 800–812.
Feng YY, Xu XQ, Ji CB, Shi CM, Guo XR, Fu JF. Aberrant hepatic microRNA expression in nonalcoholic fatty liver disease. Cell Physiol Biochem 2014; 34: 1983–1997.
Zhang J, Zhang F, Didelot X, Bruce KD, Cagampang FR, Vatish M et al. Maternal high fat diet during pregnancy and lactation alters hepatic expression of insulin like growth factor-2 and key microRNAs in the adult offspring. BMC Genomics 2009; 10: 478.
Wei S, Zhang M, Yu Y, Lan X, Yao F, Yan X et al. Berberine attenuates development of the hepatic gluconeogenesis and lipid metabolism disorder in type 2 diabetic mice and in palmitate-incubated HepG2 cells through suppression of the HNF-4alpha miR122 pathway. PLoS ONE 2016; 11: e0152097.
Jiang W, Liu J, Dai Y, Zhou N, Ji C, Li X. MiR-146b attenuates high-fat diet-induced non-alcoholic steatohepatitis in mice. J Gastroenterol Hepatol 2015; 30: 933–943.
Ortega FJ, Mercader JM, Moreno-Navarrete JM, Rovira O, Guerra E, Esteve E et al. Profiling of circulating microRNAs reveals common microRNAs linked to type 2 diabetes that change with insulin sensitization. Diabetes Care 2014; 37: 1375–1383.
Listenberger LL, Ory DS, Schaffer JE. Palmitate-induced apoptosis can occur through a ceramide-independent pathway. J Biol Chem 2001; 276: 14890–14895.
Hetherington AM, Sawyez CG, Zilberman E, Stoianov AM, Robson DL, Borradaile NM. Differential lipotoxic effects of palmitate and oleate in activated human hepatic stellate cells and epithelial hepatoma cells. Cell Physiol Biochem 2016; 39: 1648–1662.
Gao F, Jian L, Zafar MI, Du W, Cai Q, Shafqat RA et al. 4-Hydroxyisoleucine improves insulin resistance in HepG2 cells by decreasing TNF-alpha and regulating the expression of insulin signal transduction proteins. Mol Med Rep 2015; 12: 6555–6560.
Gorgani-Firuzjaee S, Meshkani R. SH2 domain-containing inositol 5-phosphatase (SHIP2) inhibition ameliorates high glucose-induced de-novo lipogenesis and VLDL production through regulating AMPK/mTOR/SREBP1 pathway and ROS production in HepG2 cells. Free Radic Biol Med 2015; 89: 679–689.
Hwang YP, Choi JH, Kim HG, Lee HS, Chung YC, Jeong HG. Saponins from Platycodon grandiflorum inhibit hepatic lipogenesis through induction of SIRT1 and activation of AMP-activated protein kinase in high-glucose-induced HepG2 cells. Food Chem 2013; 140: 115–123.
Ortega FJ, Moreno M, Mercader JM, Moreno-Navarrete JM, Fuentes-Batllevell N, Sabater M et al. Inflammation triggers specific microRNA profiles in human adipocytes and macrophages and in their supernatants. Clin Epigenetics 2015; 7: 49.
Beck JR, Shultz EK. The use of relative operating characteristic (ROC) curves in test performance evaluation. Arch Pathol Lab Med 1986; 110: 13–20.
Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3: RESEARCH0034.
Baranova A, Schlauch K, Elariny H, Jarrar M, Bennett C, Nugent C et al. Gene expression patterns in hepatic tissue and visceral adipose tissue of patients with non-alcoholic fatty liver disease. Obes Surg 2007; 17: 1111–1118.
Younossi ZM, Baranova A, Ziegler K, Del Giacco L, Schlauch K, Born TL et al. A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology 2005; 42: 665–674.
Moon YA, Liang G, Xie X, Frank-Kamenetsky M, Fitzgerald K, Koteliansky V et al. The Scap/SREBP pathway is essential for developing diabetic fatty liver and carbohydrate-induced hypertriglyceridemia in animals. Cell Metab 2012; 15: 240–246.
Nakamura A, Tajima K, Zolzaya K, Sato K, Inoue R, Yoneda M et al. Protection from non-alcoholic steatohepatitis and liver tumourigenesis in high fat-fed insulin receptor substrate-1-knockout mice despite insulin resistance. Diabetologia 2012; 55: 3382–3391.
Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215–233.
Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005; 433: 769–773.
Nielsen CB, Shomron N, Sandberg R, Hornstein E, Kitzman J, Burge CB. Determinants of targeting by endogenous and exogenous microRNAs and siRNAs. RNA 2007; 13: 1894–1910.
van Rooij E, Olson EN. MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets. J Clin Invest 2007; 117: 2369–2376.
Kohjima M, Enjoji M, Higuchi N, Kato M, Kotoh K, Yoshimoto T et al. Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease. Int J Mol Med 2007; 20: 351–358.
Naik A, Kosir R, Rozman D. Genomic aspects of NAFLD pathogenesis. Genomics 2013; 102: 84–95.
Iliopoulos D, Drosatos K, Hiyama Y, Goldberg IJ, Zannis VI. MicroRNA-370 controls the expression of microRNA-122 and Cpt1alpha and affects lipid metabolism. J Lipid Res 2010; 51: 1513–1523.
Li Y, Xu S, Mihaylova MM, Zheng B, Hou X, Jiang B et al. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab 2011; 13: 376–388.
Hardie DG. AMPK: a key regulator of energy balance in the single cell and the whole organism. Int J Obes (Lond) 2008; 32: S7–S12.
Kim K, Pyo S, Um SH. S6 kinase 2 deficiency enhances ketone body production and increases peroxisome proliferator-activated receptor alpha activity in the liver. Hepatology 2012; 55: 1727–1737.
Mihaylova MM, Shaw RJ. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat Cell Biol 2011; 13: 1016–1023.
Szabo G, Bala S. MicroRNAs in liver disease. Nat Rev Gastroenterol Hepatol 2013; 10: 542–552.
Wang B, Majumder S, Nuovo G, Kutay H, Volinia S, Patel T et al. Role of microRNA-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid-defined diet in C57BL/6 mice. Hepatology 2009; 50: 1152–1161.
Song KH, Li T, Owsley E, Chiang JY. A putative role of micro RNA in regulation of cholesterol 7alpha-hydroxylase expression in human hepatocytes. J Lipid Res 2010; 51: 2223–2233.
Zhang J, Yang Y, Yang T, Yuan S, Wang R, Pan Z et al. Double-negative feedback loop between microRNA-422a and forkhead box (FOX)G1/Q1/E1 regulates hepatocellular carcinoma tumor growth and metastasis. Hepatology 2015; 61: 561–573.
Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005; 438: 685–689.
Esau C, Davis S, Murray SF, Yu XX, Pandey SK, Pear M et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 2006; 3: 87–98.
Tsai WC, Hsu SD, Hsu CS, Lai TC, Chen SJ, Shen R et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest 2012; 122: 2884–2897.
Hsu SH, Wang B, Kota J, Yu J, Costinean S, Kutay H et al. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest 2012; 122: 2871–2883.
Huang YH, Lin KH, Chen HC, Chang ML, Hsu CW, Lai MW et al. Identification of postoperative prognostic microRNA predictors in hepatocellular carcinoma. PLoS ONE 2012; 7: e37188.
Zhang X, Daucher M, Armistead D, Russell R, Kottilil S. MicroRNA expression profiling in HCV-infected human hepatoma cells identifies potential anti-viral targets induced by interferon-alpha. PLoS ONE 2013; 8: e55733.
Hilton C, Neville MJ, Karpe F. MicroRNAs in adipose tissue: their role in adipogenesis and obesity. Int J Obes (Lond) 2013; 37: 325–332.
Hsieh CH, Rau CS, Wu SC, Yang JC, Wu YC, Lu TH et al. Weight-reduction through a low-fat diet causes differential expression of circulating microRNAs in obese C57BL/6 mice. BMC Genomics 2015; 16: 699.
Huang Y, Chen HC, Chiang CW, Yeh CT, Chen SJ, Chou CK. Identification of a two-layer regulatory network of proliferation-related microRNAs in hepatoma cells. Nucleic Acids Res 2012; 40: 10478–10493.
Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA 2006; 103: 12481–12486.